A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

MLA

Han W. Tun, et al. “A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies.” Blood, vol. 136, Nov. 2020, pp. 49–50. EBSCOhost, https://doi.org/10.1182/blood-2020-140884.

APA

Han W. Tun, Monica Mead, Daniel J. Landsburg, Grzegorz S. Nowakowski, Allison C. Rosenthal, Lori A. Leslie, Radhakrishnan Ramchandren, Erel Joffe, Krish Patel, Christopher Lieberman, Alan P Skarbnik, Praveen Ramakrishnan Geethakumari, Elizabeth Ferreira Martinez, Timothy S. Fenske, Reinhard von Roemeling, & Matthew A. Lunning. (2020). A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 136, 49–50. https://doi.org/10.1182/blood-2020-140884

Chicago

Han W. Tun, Monica Mead, Daniel J. Landsburg, Grzegorz S. Nowakowski, Allison C. Rosenthal, Lori A. Leslie, Radhakrishnan Ramchandren, et al. 2020. “A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies.” Blood 136 (November): 49–50. doi:10.1182/blood-2020-140884.